Alpha 2.0
Login Register
» Articles » PMID: 18551180

The Metabolism and Transplacental Transfer of Oseltamivir in the Ex Vivo Human Model

Overview
Journal Infect Dis Obstet Gynecol
Publisher Wiley
Specialties Gynecology & Obstetrics
Infectious Diseases
Date 2008 Jun 14
PMID 18551180
Citations 16
Authors
Kevin C Worley
Scott W Roberts
Roger E Bawdon
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Oseltamivir phosphate is extensively metabolized in the ex vivo human placenta model, and the transplacental passage of the metabolite oseltamivir carboxylate is incomplete.

Objective: To evaluate the metabolism and transplacental transfer of oseltamivir (Tamiflu) in the ex vivo human placental model.

Study Design: Perfusion studies were performed in six placentas from term, uncomplicated deliveries. Concentrations of oseltamivir phosphate (OP) that were 5-6 fold, 20-30 fold, and 600-800 fold above the therapeutic peak were tested, as neither OP nor its active metabolite, oseltamivir carboxylate (OC), could be detected at near-therapeutic concentrations. The transplacental transfer and accumulation of OC were assessed using the (14)C antipyrine reference method.

Results: OP was extensively metabolized to OC. In the 4 placentas with the highest concentration of OP, OC had a mean clearance index of 0.13 +/- 0.08, suggesting that transplacental passage occurs at a relatively low rate. Measurable fetal accumulation occurred in the two placentas with the highest initial concentrations.

Conclusions: Oseltamivir phosphate was extensively metabolized in the ex vivo model. Transplacental transfer of the metabolite was incomplete and accumulation was minimal.

Citing Articles

Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy.

Chow E, Beigi R, Riley L, Uyeki T Open Forum Infect Dis. 2021; 8(6):ofab138.

PMID: 34189160 PMC: 8232385. DOI: 10.1093/ofid/ofab138.

HPLC Method for Quantification of Caffeine and Its Three Major Metabolites in Human Plasma Using Fetal Bovine Serum Matrix to Evaluate Prenatal Drug Exposure.

Lopez-Sanchez R, Lara-Diaz V, Aranda-Gutierrez A, Martinez-Cardona J, Hernandez J J Anal Methods Chem. 2018; 2018:2085059.

PMID: 30186659 PMC: 6109507. DOI: 10.1155/2018/2085059.

Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study.

Graner S, Svensson T, Beau A, Damase-Michel C, Engeland A, Furu K BMJ. 2017; 356:j629.

PMID: 28246106 PMC: 5421412. DOI: 10.1136/bmj.j629.

Oseltamivir for influenza in pregnancy.

Beigi R, Venkataramanan R, Caritis S Semin Perinatol. 2014; 38(8):503-7.

PMID: 25281358 PMC: 5745365. DOI: 10.1053/j.semperi.2014.08.015.

The placenta in toxicology. Part IV: Battery of toxicological test systems based on human placenta.

Gohner C, Svensson-Arvelund J, Pfarrer C, Hager J, Faas M, Ernerudh J Toxicol Pathol. 2013; 42(2):345-51.

PMID: 23548605 PMC: 4162308. DOI: 10.1177/0192623313482206.

References
1.
Fiore A, Shay D, Haber P, Iskander J, Uyeki T, Mootrey G . Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007; 56(RR-6):1-54. View
2.
Moscona A . Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353(13):1363-73. DOI: 10.1056/NEJMra050740. View
3.
Lindegardh N, Davies G, Tran T, Farrar J, Singhasivanon P, Day N . Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother. 2006; 50(9):3197-9. PMC: 1563560. DOI: 10.1128/AAC.00500-06. View
4.
Schneider H, Huch A . Dual in vitro perfusion of an isolated lobe of human placenta: method and instrumentation. Contrib Gynecol Obstet. 1985; 13:40-7. View
5.
Shu Y, Yu H, Li D . Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui Province, China. N Engl J Med. 2006; 354(13):1421-2. DOI: 10.1056/NEJMc053524. View